Gilead Sciences said Wednesday that its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30% — a clinical trial result that could lead to a better treatment option for patients with advanced disease and strengthen the drug’s commercial outlook.
In the study, called TROPICS-02, Trodelvy showed a median overall survival of 14.4 months compared to 11.2 months for comparator chemotherapy. The survival benefit of 3.2 months was statistically significant and translated into a 21% reduction in the risk of death.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED"breast" - Google News
September 08, 2022 at 05:13AM
https://ift.tt/vLP58yJ
Gilead drug prolongs survival of women with form of breast cancer - STAT
"breast" - Google News
https://ift.tt/mNA1Zgj
https://ift.tt/jSPMc3C
Bagikan Berita Ini
0 Response to "Gilead drug prolongs survival of women with form of breast cancer - STAT"
Post a Comment